Helixgate

Helixgate

Uncategorized

STAT+: Up and down the ladder: The latest comings and goings

Published

on

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going.

And here is our regular feature in which we highlight a different person each week. This time around, we note that Ailux hired Maria Belvisi as chief scientific officer. Previously, she worked at AstraZeneca, where she was senior vice president, research and development, respiratory & immunology, biopharmaceuticals R&D.

But all work and no play can make for a dull chief scientific officer.

Continue to STAT+ to read the full story…

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Opinion: Why the space in ‘health care’ matters

Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Sarah Mupo. Be sure to sign up for the weekly “First Opinion Podcast” on Apple PodcastsSpotify, or wherever you get your podcasts. Get alerts about each new episode by signing up for the “First Opinion Podcast” newsletter. And don’t forget to sign up for the First Opinion newsletter, delivered every Sunday.

Torie Bosch: In recent years, there’s been a quiet shift in medicine. I’m not talking about a new drug or a new insurance headache. I’m talking about the way we write “health care.” Historically, it’s been two words. But increasingly, people, especially in the industry, have changed it to one word. At STAT, perhaps no linguistic decision is as important as: Should “health care” be one word or two?

Read the rest…

Read More

Published

on

Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Sarah Mupo. Be sure to sign up for the weekly “First Opinion Podcast” on Apple PodcastsSpotify, or wherever you get your podcasts. Get alerts about each new episode by signing up for the “First Opinion Podcast” newsletter. And don’t forget to sign up for the First Opinion newsletter, delivered every Sunday.

Torie Bosch: In recent years, there’s been a quiet shift in medicine. I’m not talking about a new drug or a new insurance headache. I’m talking about the way we write “health care.” Historically, it’s been two words. But increasingly, people, especially in the industry, have changed it to one word. At STAT, perhaps no linguistic decision is as important as: Should “health care” be one word or two?

Read the rest…

Read More

Continue Reading

Uncategorized

Denali sells FDA voucher for $195M to support neurodegenerative pipeline

Published

on

Denali Therapeutics is the latest company to sell a priority review fast pass for an elevated price after the program was renewed earlier this year.

Continue Reading

Uncategorized

US launches investigation into German drug pricing, citing unfair R&D burden

Published

on

The U.S. government has argued that it pays too much of biopharma R&D costs, demanding that other high-income countries contribute fairly to global innovation efforts.

Continue Reading
Advertisement

Trending